Aclaris Therapeutics earnings were -$130.2M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest ACRS earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$15.1M, down 84.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ACRS reported annual earnings of -$132.1M, with 49.3% growth.
Aclaris Therapeutics Earnings Reports & History FAQ
What were Aclaris Therapeutics's earnings last quarter?
On ACRS's earnings call on Invalid Date, Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 2025 earnings per share (EPS) of -$0.12, up 50% year over year. Total ACRS earnings for the quarter were -$15.09 million. In the same quarter last year, Aclaris Therapeutics's earnings per share (EPS) was -$0.24.
Is Aclaris Therapeutics profitable or losing money?
As of the last Aclaris Therapeutics earnings report, Aclaris Therapeutics is currently losing money. Aclaris Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$130.21 million, a 68.53% increase year over year.
What was ACRS's earnings growth in the past year?
As of Aclaris Therapeutics's earnings date in Invalid Date, Aclaris Therapeutics's earnings has grown year over year. ACRS earnings in the past year totalled -$130.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.